gip and glp 1 drugs The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology GLP-1 and Dual GIP/GLP-1 Agonists

Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

Incretin action of GIP is dramatically reduced in the presence of diabetes, as demonstrated by the evidence that glucose-dependent insulin secretion is not potentiated by GIP administration in subjects with diabetes [33, 34]

Saxenda is administered once a day by subcutaneous injection

However, the largest roadblock remains the cost of covering GLP-1s